Literature DB >> 26728725

Analysis of informativeness of immunohistochemical and flow cytometric methods for estrogen receptor α assessment.

T A Bogush1, E A Dudko2, M V Rodionova2, E A Bogush2, V J Kirsanov2, V V Rodionov3, I K Vorotnikov2.   

Abstract

Informative capacity analysis of immunohistochemistry (IHC) and flow cytometry (FCM) in the assessment of estrogen receptor α (ERα) expression in breast cancer tissue was performed. Similar frequencies of expression were shown by both methods: 27% of ERα-negative and 73% ERα-positive cases. However, IHC evaluation detected low levels in only 20% of ERα-positive cases, whereas low levels of ERα detected by FCM were 2 times more often (48%). Moreover, FCM revealed positive expression (23-60%) in 33% of IHC ERα-negative cases. Among IHC ER-positive cases, zero ERα expression was detected by FCM in 12.5%. The approaches to minimize errors in routine clinical determination of the estrogen receptor status were proposed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26728725     DOI: 10.1134/S1607672915060058

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN: 1607-6729            Impact factor:   0.788


  9 in total

Review 1.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

Authors:  A Goldhirsch; J H Glick; R D Gelber; H J Senn
Journal:  J Natl Cancer Inst       Date:  1998-11-04       Impact factor: 13.506

2.  Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma.

Authors:  David J Dabbs; Rodney J Landreneau; Yulin Liu; Stephen S Raab; Richard H Maley; Ming Y Tung; Jan F Silverman
Journal:  Ann Thorac Surg       Date:  2002-02       Impact factor: 4.330

3.  Development of new rabbit monoclonal antibody to estrogen receptor: immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections.

Authors:  Zhida Huang; Weimin Zhu; George Szekeres; Haiying Xia
Journal:  Appl Immunohistochem Mol Morphol       Date:  2005-03

Review 4.  [Estrogen receptor expression in tumors different from breast cancer].

Authors:  T A Bogush; E A Dudko; A A Beme; E A Bogush; B E Polotskiĭ; S A Tiuliandin; M I Davydov
Journal:  Antibiot Khimioter       Date:  2009

Review 5.  Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer.

Authors:  Pierre-Emmanuel Colombo; Michel Fabbro; Charles Theillet; Frédéric Bibeau; Philippe Rouanet; Isabelle Ray-Coquard
Journal:  Crit Rev Oncol Hematol       Date:  2013-09-08       Impact factor: 6.312

6.  Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer.

Authors:  Carmen Gomez-Fernandez; Yahya Daneshbod; Mehdi Nassiri; Clara Milikowski; Consuelo Alvarez; Mehrdad Nadji
Journal:  Am J Clin Pathol       Date:  2008-12       Impact factor: 2.493

7.  Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.

Authors:  Jan Nyrop Jakobsen; Eric Santoni-Rugiu; Jesper Ravn; Jens Benn Sørensen
Journal:  Eur J Cancer       Date:  2013-04-29       Impact factor: 9.162

8.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Authors:  A Goldhirsch; J N Ingle; R D Gelber; A S Coates; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2009-06-17       Impact factor: 32.976

9.  Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence.

Authors:  C Kamby; B B Rasmussen; B Kristensen
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

  9 in total
  2 in total

1.  Flow cytometric analysis of the ERCC1, marker of DNA damage repair, in the tumor specimens embedded into paraffin blocks.

Authors:  T A Bogush; E A Dudko; A N Grishanina; V T Zarkua; E A Bogush; A A Basharina; B E Polotsky; S A Tjulandin; M M Davydov; M I Davydov
Journal:  Dokl Biochem Biophys       Date:  2017-04-19       Impact factor: 0.788

2.  The expression and clinical significance of ERβ/ERα in ovarian cancer: can we predict the effectiveness of platinum plus taxane therapy?

Authors:  Tatiana A Bogush; Anna A Basharina; Elena A Bogush; Alexander M Scherbakov; Mikhail M Davydov; Vyacheslav S Kosorukov
Journal:  Ir J Med Sci       Date:  2021-11-06       Impact factor: 2.089

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.